Eps8L2 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src family kinase inhibitor that by targeting Src kinases, which are upstream regulators of actin filament dynamics and can phosphorylate substrates like Eps8L2, dasatinib inhibits actin polymerization. Through this action, it indirectly inhibits Eps8L2 by preventing its interaction with Src kinases, leading to reduced activity of Eps8L2 in actin remodeling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Another Src family kinase inhibitor, PP2, prevents the activation of Src kinases which are potentially responsible for the phosphorylation of Eps8L2. Inhibiting Src kinases would lead to decreased phosphorylation and subsequent activation of Eps8L2, thereby reducing its role in actin cytoskeleton reorganization. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that impedes the Rho-associated, coiled-coil containing protein kinase (ROCK). Since ROCK is key to actin cytoskeleton dynamics and Eps8L2 is involved in actin filament capping and bundling, Y-27632 indirectly inhibits Eps8L2's functionality by stabilizing actin filaments and preventing their reorganization. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
By binding to monomeric G-actin, Latrunculin A prevents the polymerization into F-actin, thus indirectly inhibiting Eps8L2's role in actin filament capping and bundling. Without available F-actin, Eps8L2 cannot exert its function on actin dynamics. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
An inhibitor of actin polymerization, Cytochalasin D binds to the barbed ends of actin filaments, preventing the addition of new monomers. Eps8L2, which modulates actin filament dynamics, is indirectly inhibited as it relies on functional filaments to exert its capping activity. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
An inhibitor of myosin light chain kinase (MLCK), ML7 indirectly affects Eps8L2 by altering the contractility of actin filaments and myosin, potentially disrupting the cellular locations where Eps8L2 exerts its activity on actin remodeling. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
By inhibiting myosin II, Blebbistatin interferes with actin-myosin interactions and thus with actin cytoskeleton dynamics. This affects Eps8L2's ability to bind and cap actin filaments, indirectly leading to its inhibition. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
An Arp2/3 complex inhibitor, CK-666 prevents actin nucleation and branching. Since Eps8L2 is involved in actin capping and bundling, the decrease in actin branching indirectly inhibits Eps8L2's functional contributions to actin architecture. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
An inhibitor of formin homology 2 domains, SMIFH2 disrupts formin-mediated actin nucleation and elongation. This indirectly inhibits Eps8L2 by limiting the availability of actin structures for Eps8L2 to cap and bundle. | ||||||
PF-3758309 | 898044-15-0 | sc-478493 | 10 mg | $260.00 | ||
A potent inhibitor of protein kinase D (PKD), PF-3758309 can indirectly inhibit Eps8L2 by affecting actin cytoskeleton dynamics, as PKD is involved in the regulation of actin remodeling processes that Eps8L2 is known to participate in. | ||||||